Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $661.8552W HIGH $1,072.75
Volume
512.25 K
Value Traded
314.65 M
Short % Float
2.09%
-9.62%Week
-16.16%1 Month
-5.85%3 Month
+1.95%6 Month
+197.06%5 Year
+4,405.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
51.61 B
EPS (TTM)
21.10
P/E Ratio
39.11
Ent. Value
45.93 B
Total Shares
62.56 M
Float Shares
62.76 M
Insiders
0.19%
Institutions
45.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ARGX Catalyst Timeline
Dated clinical, regulatory and corporate events for argenx SE
Catalyst Timeline
Dated clinical, regulatory & corporate events for argenx SE
758Total events
18Upcoming
242Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Primary Endpoint MetFB102Clinical Data
FB102 met primary endpoint of change from baseline in Vh:Cd at day 78 (p=0.0176)
celiac diseasesource ↗
▲Topline ReadoutFB102Clinical Data
Positive topline results from Phase 2 study of FB102 in celiac disease
celiac diseasesource ↗
▼Trial Stopped FutilityEfgartigimodApprovedTrial
argenx discontinues Phase 3 UNITY study of efgartigimod SC in Sjögren's disease for futility
Sjögren's diseasesource ↗
▼Interim AnalysisEfgartigimodApprovedTrial
Interim analysis of Phase 3 UNITY study led to futility recommendation
Sjögren's diseasesource ↗
▼Trial DiscontinuedEfgartigimodApprovedTrial
Phase 3 UNITY study of efgartigimod SC in Sjögren's disease discontinued
Sjögren's diseasesource ↗
▲Oral PresentationEfgartigimodApprovedPresentation
Efgartigimod in AChR Antibody Negative gMG: Efficacy and Safety Results from ADAPT SERON
Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravissource ↗
▲Poster PresentationEmpasiprubartPresentation
Phase 2 ARDA+ results showing sustained clinical benefit of empasiprubart in MMN presented at AANEM
Multifocal Motor Neuropathy (MMN)source ↗
▲Poster PresentationEfgartigimodApprovedPresentation
Longitudinal analysis of response as first-line treatment with VYVGART Hytrulo in CIDP presented at AANEM
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)source ↗
▲Poster PresentationAdimanebartPresentation
Phase 1b digital gait outcomes of adimanebart in DOK7-CMS presented at AANEM
DOK7-Congenital Myasthenic Syndromes (CMS)source ↗
●Poster PresentationPresentation
Understanding the Patient Journey in MMN: Descriptive Insights From the iMMersioN Study
Multifocal Motor Neuropathysource ↗
▲Oral PresentationEfgartigimodApprovedPresentation
Sustained Efficacy in anti-AChR antibody-negative MG (MGFA Oral #72)
Generalized Myasthenia Gravis (anti-AChR antibody-negative)source ↗
▲Poster PresentationEfgartigimodApprovedPresentation
Early Grip Strength Improvement in CIDP (AANEM Poster #343)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)source ↗
▲Oral PresentationEfgartigimodApprovedPresentation
One-year ADAPT SERON results in anti-AChR antibody-negative gMG presented at MGFA
Generalized Myasthenia Gravis (anti-AChR antibody-negative)source ↗
●Poster PresentationEfgartigimodApprovedPresentation
Real-world evidence on disease burden in AChR-Ab-negative vs positive gMG from MyaReg presented at MGFA
Generalized Myasthenia Gravissource ↗
●Corporate ApprovalCorporate
argenx shareholders approve resolutions at Extraordinary General Meeting
●Management ChangeCorporate
Thomas M. Brakel and Khurem Farooq appointed as Non-Executive Directors
▲Primary Endpoint MetClinical Data
ALKIVIA met primary endpoint of mean TIS at Week 52
autoimmune myositissource ↗
▲Topline ReadoutClinical Data
Positive topline results from Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis
autoimmune myositissource ↗
▲Quarterly UpdateCorporate
Half Year 2026 Financial Results and Second Quarter Business Update
▲Partnership / LicenseCorporate
Collaboration agreement with Chai Discovery for AI-driven antibody discovery
◆Topline ReadoutEfgartigimodApprovedClinical Data
Topline results from registrational ALKIVIA study (myositis) expected
myositissource ↗
●R&D DayPresentation
R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis Webinar
▲Poster PresentationEfgartigimodApprovedPresentation
Poster presentation of cross-indication safety analysis at EULAR 2026
multiple autoimmune diseasessource ↗
▲Poster PresentationEfgartigimodApprovedPresentation
Poster presentation of ALKIVIA+ long-term safety and efficacy results at EULAR 2026
myositissource ↗
▲Oral PresentationEfgartigimodApprovedPresentation
Oral presentation of RHO+ long-term efficacy and safety results at EULAR 2026
Sjogren's diseasesource ↗
◆Additional DataEmpasiprubartClinical Data
52-week efficacy analysis for VARVARA (DGF) expected mid-year 2026
delayed graft function (DGF)source ↗
◆Oral PresentationPresentation
argenx CEO to present at BofA Securities 2026 Health Care Conference
◆PDUFA DateEfgartigimodApprovedRegulatory Filing
PDUFA target action date for seronegative gMG
anti-acetylcholine receptor antibody negative (AChR-Ab-) generalized myasthenia gravis (gMG)source ↗
▲Supplemental ApprovalEfgartigimodApprovedFDA Decision
FDA approved label expansion for VYVGART and VYVGART Hytrulo for all serotypes of adult gMG
generalized myasthenia gravissource ↗
▲Primary Endpoint MetEfgartigimodApprovedClinical Data
ADAPT SERON met primary endpoint (p=0.0068) showing MG-ADL improvement at week 4
generalized myasthenia gravis (seronegative)source ↗
▲Topline ReadoutClinical Data
Positive top-line results from ADAPT OCULUS study of VYVGART Hytrulo in ocular MG
ocular myasthenia gravissource ↗
●Trial InitiationEfgartigimodApprovedTrial
ADAPT Jr study ongoing in pediatric gMG patients
generalized myasthenia gravis (pediatric)source ↗
▲Topline ReadoutEfgartigimodApprovedClinical Data
Positive topline results from ADAPT OCULUS presented at AAN
ocular myasthenia gravis (oMG)source ↗
●Quarterly UpdateCorporate
Annual General Meeting held with 90.9% share capital represented; all agenda items approved
◆Management ChangeCorporate
Karen Massey to become CEO, Tim Van Hauwermeiren to become Chairman, subject to shareholder approval
◆Poster PresentationEfgartigimodApprovedPresentation
Assessing Efgartigimod Dosing Patterns and Myasthenia Gravis Activities of Daily Living Outcomes in Clinical Practice: Results From a Large Patient Support Program Database in the United States
Generalized Myasthenia Gravis (gMG)source ↗
◆Poster PresentationEfgartigimodApprovedPresentation
Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)source ↗
◆Poster PresentationEmpasiprubartPresentation
Design of a Phase 2a Study to Evaluate the Safety, Efficacy, and Tolerability of Intravenous Empasiprubart as an Add-On Therapy to Intravenous Efgartigimod in Adult Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG)source ↗
◆Oral PresentationAdimanebartPresentation
Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Participants with DOK7 Congenital Myasthenic Syndromes
DOK7 Congenital Myasthenic Syndromes (CMS)source ↗
◆Oral PresentationEfgartigimodApprovedPresentation
Efficacy and Safety of Efgartigimod in Anti-acetylcholine Receptor Antibody-Negative Generalized Myasthenia Gravis: Initial Results of ADAPT SERON
Generalized Myasthenia Gravis (gMG)source ↗
◆Poster PresentationEfgartigimodApprovedPresentation
Real-world Effectiveness and Use of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE REAL Study Design
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)source ↗
Past FDA Catalysts and PDUFA Decisions
How ARGX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-02 | VYVGART (efgartigimod alfa-fcab) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C54 / 100
Pipeline Score
$3.5B
Pipeline Value
$22.4B
Commercial Value
Overvalued
Valuation Signal
15
Drugs Scored
0.1x
rNPV / MCap
Top 12%
Large Pharma(rank 80 of 660)
Percentile Rank
argenx SE carries a moderate pipeline score (54/100), with $3.5B risk-adjusted pipeline value, led by Empasiprubart in Multifocal Motor Neuropathy (MMN) (Phase 3), across $82B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K)) Revenue $5.2B x 4.3 = $22.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| VYVGART | $5.2B | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Empasiprubart Monoclonal antibodyNCT06920004 | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | RECRUITING | 378 | Sep 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARGX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARGX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.3 % (15.3 %) | 927.77 M | 1.00 M |
ARGX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARGX ranks across every disease it competes in
Competitive Position is a premium feature
See how ARGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARGX News
ARGX▼ -11.8%on this news
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
argenx announced positive topline results from a Phase 2 study of FB102, a CD122 inhibitor, in adults with celiac disease. The study met its primary endpoint, showing a significant change in the villus height-to-crypt depth ratio compared to placebo. The safety profile was consistent with prior studies, and argenx plans to advance FB102 into Phase 3 development.
Read more →ARGX▼ -11.8%on this news
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
argenx SE has announced the discontinuation of its Phase 3 UNITY study of efgartigimod SC in Sjögren's disease, following a recommendation from an Independent Data Monitoring Committee. The study was halted for futility after an interim analysis indicated it could not meet its primary endpoint. Despite consistent safety profiles, this outcome is a setback for patients awaiting effective treatments.
Read more →ARGXargenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
argenx presented new data at the AANEM and MGFA sessions, highlighting VYVGART's effectiveness in treating myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The data showed significant improvements in ocular MG and sustained efficacy in patients without detectable anti-AChR antibodies. Additionally, real-world evidence indicated that earlier treatment with VYVGART leads to better patient outcomes.
Read more →ARGXargenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
argenx SE announced the results of its Extraordinary General Meeting, appointing Thomas M. Brakel and Khurem Farooq as non-executive directors. The company emphasizes its commitment to scientific innovation and enhancing shareholder value. The appointments are seen as a strategic move to strengthen the Board as argenx aims for long-term growth and impact in immunology.
Read more →ARGXBenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
BenchSci has entered into a two-year enterprise agreement with argenx to implement its AI-driven research environment, EMET, for preclinical drug discovery. This collaboration was chosen through a competitive evaluation by argenx's scientists and marks a significant step for BenchSci's expansion in the European biopharma market. The partnership aims to enhance the efficiency of drug discovery processes.
Read more →ARGXargenx to Present at Upcoming Investor Conferences
argenx announced its participation in two upcoming investor conferences in September 2026. The management team will engage in fireside chats at the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Live webcasts of these presentations will be available on the company's website.
Read more →ARGX▲ +16%on this news
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
argenx announced positive topline results from the Phase 3 ALKIVIA trial of efgartigimod in patients with autoimmune myositis. The study met its primary endpoint, demonstrating a significant improvement in the Total Improvement Score at 52 weeks. Efgartigimod showed consistent benefits across both IMNM and DM subtypes, marking a significant advancement in treatment options for these patients.
Read more →ARGXargenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
argenx SE has announced an Extraordinary General Meeting of Shareholders scheduled for September 17, 2026, in Amsterdam. The meeting will focus on the proposed appointments of two new non-executive directors to the Board. Shareholders are encouraged to attend in person or vote by proxy, with detailed information available on the company's website.
Read more →ARGXargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
argenx has announced its acquisition of Forte Biosciences for $77 per share, totaling approximately $2.2 billion. This strategic move aims to enhance argenx's immunology portfolio by adding FB102, a first-in-class anti-CD122 antibody. The acquisition reflects argenx's commitment to expanding its innovative treatment options in immunology.
Read more →ARGX▲ +8.6%on this newsshared move
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
argenx reported strong financial results for the second quarter of 2026, with $1.5 billion in global product net sales, marking a 60% increase year-over-year. The company successfully launched expanded indications for VYVGART and VYVGART Hytrulo, now covering all gMG serotypes. Key registrational study readouts are expected in the second half of 2026, supporting the company's growth strategy.
Read more →ARGXargenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
argenx has announced a conference call scheduled for July 23, 2026, to discuss its half-year financial results and provide a business update for the second quarter. The call will be accessible via a webcast and various international dial-in numbers. The company focuses on developing treatments for severe autoimmune diseases.
Read more →ARGXChai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs
Chai Discovery has entered a collaboration agreement with argenx to utilize its AI platform for antibody discovery. This partnership aims to enhance therapeutic targets through advanced computational design. Argenx, recognized for its robust antibody development capabilities, will integrate Chai's technology to further its immunology innovations.
Read more →ARGX▼ -5.6%on this news
argenx to Host Autoimmune Myositis R&D Webinar
argenx is hosting a webinar on June 23, 2026, focusing on autoimmune myositis and their advancements in FcRn leadership. The event will feature key opinion leaders from prestigious institutions discussing the latest research and developments. A live webcast will be available, along with supporting materials on their website.
Read more →ARGXargenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Argenx presented new data on efgartigimod at EULAR 2026, demonstrating its long-term benefits in myositis and Sjogren's disease. The ALKIVIA+ study showed sustained improvements in myositis patients, while the RHO+ study confirmed maintenance of response in Sjogren's disease. Efgartigimod's safety profile remained consistent across various autoimmune conditions.
Read more →ARGXargenx to Host Myositis R&D Webinar on June 23, 2026
argenx announced a webinar titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis' scheduled for June 23, 2026. This event is part of a mini-series aimed at showcasing the company's research and development strategy. The webinar will feature discussions on myositis, including disease biology and the ALKIVIA clinical program for efgartigimod.
Read more →ARGXargenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
argenx announced that the FDA has approved a label expansion for VYVGART and VYVGART Hytrulo, allowing their use in all adult patients with generalized myasthenia gravis (gMG), including those without detectable anti-AChR antibodies. This approval is based on the Phase 3 ADAPT SERON study, which demonstrated significant symptom improvements in patients treated with VYVGART. The expansion aims to meet the needs of a broader range of gMG patients, simplifying treatment decisions for clinicians.
Read more →ARGXargenx Reports First Quarter 2026 Financial Results and Provides Business Update
argenx SE reported a robust first quarter for 2026, achieving $1.3 billion in global product net sales, marking a 63% increase year-over-year. The company is optimistic about the upcoming PDUFA date for anti-AChR antibody negative gMG on May 10, 2026, and is advancing its pipeline with several candidates expected to enter registrational studies. argenx aims to treat 50,000 patients globally by 2030 and is expanding its leadership in FcRn therapies.
Read more →ARGXargenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
argenx SE has announced the appointment of Karen Massey as Chief Executive Officer, succeeding Tim Van Hauwermeiren, who will now serve as Chairperson of the Board. The transition follows a successful Annual General Meeting where shareholders approved all agenda items. Massey, who joined the company in March 2023, is expected to lead the next phase of growth for argenx.
Read more →ARGXargenx to Present at BofA Securities 2026 Health Care Conference
argenx announced that CEO Karen Massey will present at the BofA Securities 2026 Health Care Conference on May 12, 2026. The presentation will focus on the company's advancements in treating severe autoimmune diseases. A live webcast will be available, along with a replay for 30 days post-event.
Read more →About argenx SE
BIOPHARMAWATCH ELITE PLUS
Trade the next ARGX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime